GSK to get less from Zhifei shingles vaccine deal; to collaborate on RSV
China's Zhifei will pay GSK about 2.3 billion pounds ($2.9 billion) for the exclusive rights to distribute GSK's shingles ...
FiercePharma6d
GSK cuts Shingrix deliveries in revised Zhifei China pact, moves closer to RSV vaccine deal
Under the revised agreement, the two have taken their RSV commitment a step forward as Zhifei agrees to engage exclusively ...
GSK expands deal with China's Zhifei to explore RSV vaccine collaboration
GSK said on Thursday it had expanded its agreement with China's largest vaccine company Zhifei to explore a potential ...
FiercePharma5d
Fierce Pharma Asia—Sanofi's $1B manufacturing base; GSK's ADC deal, Shingrix recalibration in China
Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in ...
The Pharma Letter6d
GSK expands vaccine collaboration in China with Zhifei
UK pharma major GSK has into an agreement with Chongqing Zhifei Biological Products (Zhifei) to revize the terms on which ...
GSK, Zhifei Revise And Extend Strategic Vaccine Collaboration In China
GSK plc (GSK, GSK.L), on Thursday, said it has agreed with Chongqing Zhifei Biological Products Ltd. to revise the terms on which ...
Wall Street Journal6d
GSK, China’s Zhifei Extend Shingles Shot Collaboration to 2034
GSK PLCGSK3.09%increase; green up pointing triangle extended its collaboration with Chongqing Zhifei Biological Products 300122-1.12%decrease; red down pointing triangle to commercialize its ...
Reuters7d
GSK to get less from Zhifei shingles vaccine deal; to collaborate on RSV
Revised deal with Zhifei to manage near-term challenges GSK shares marginally lower Potential RSV collaboration for initial 10-year term Dec 5 (Reuters) - China's Zhifei (300122.SZ), opens new tab ...
GSK, Zhifei revise, extend strategic vaccine collaboration in China
GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will ...
Morningstar7d
GSK, China's Zhifei Extend Shingles Shot Collaboration to 2034
GSK PLC extended its collaboration with Chongqing Zhifei Biological Products to commercialize its shingles vaccine Shingrix in China until 2034. The British pharma company said Thursday that it ...
Pharmabiz6d
GSK and Zhifei revise and extend strategic vaccine collaboration in China
GSK and Zhifei revise and extend strategic vaccine collaboration in China: London, UK Friday, December 6, 2024, 10:00 Hrs [IST] GSK plc announced that it has entered into an agree ...
Nasdaq6d
GSK, Zhifei revise, extend strategic vaccine collaboration in China
GSK (GSK) announced that it has entered into an agreement with Chongqing Zhifei Biological Products to revise the terms on which Zhifei will commercialise GSK’s shingles vaccine, Shingrix ...